Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Lung Cancer

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0169-5002(02)00180-0PMID 12399121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

  2004cited by this paper
• Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B

  2004cited by this paper
• A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma

  2004cited by this paper
• A phase II study of m-AMSA in patients with malignant mesothelioma

  2004cited by this paper
• A phase II study of vincristine in malignant mesothelioma — a negative report

  2004cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).

  2003cited by this paper
• Surgical treatment of malignant pleural mesothelioma: a review.

  2003cited by this paper
• Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.

  2003cited by this paper
• Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma

  2002cited by this paper
• Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma

  2002cited by this paper
• Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

  2002cited by this paper
• A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

  2002cited by this paper
• Malignant pleural mesothelioma: a phase II trial with docetaxel.

  2002cited by this paper
• Oxaliplatin and Raltitrexed in the Treatment of Inoperable Malignant Pleural Mesothelioma: Results of a Pilot Study

  2001cited by this paper
• Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma

  2001cited by this paper
• Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.

  2001cited by this paper
• Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

  2001cited by this paper
• A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.

  2001cited by this paper
• Combination Chemotherapy With Mitoxantrone, Methotrexate, and Mitomycin (MMM Regimen) in Malignant Pleural Mesothelioma: A Phase II Study

  2001cited by this paper
• Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

  2001cited by this paper
• Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

  2001cited by this paper
• Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

  2000cited by this paper
• Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

  2000cited by this paper
• Caelyx in malignant mesothelioma: a phase II EORTC study.

  2000cited by this paper
• A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

  2000cited by this paper
• Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study

  2000cited by this paper
• Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma

  1999cited by this paper
• A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

  1999cited by this paper
• Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura

  1999cited by this paper
• Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.

  1999cited by this paper
• Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.

  1999cited by this paper
• Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma

  1999cited by this paper
• High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

  1999cited by this paper
• Ifosfamide in malignant mesothelioma: a phase II study.

  1999cited by this paper
• A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.

  1999cited by this paper
• Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

  1999cited by this paper
• A phase II study of gemcitabine in patients with malignant pleural mesothelioma

  1999cited by this paper
• High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma

  1999cited by this paper
• Phase II trial of topotecan for the treatment of mesothelioma.

  1998cited by this paper
• Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.

  1998cited by this paper
• Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.

  1998cited by this paper
• Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors

  1998cited by this paper
• A review of chemotherapy trials for malignant mesothelioma.

  1998influential reference
• [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer].

  1998cited by this paper
• Maintenance chemotherapy for small cell lung cancer: a critical review of the literature.

  1998cited by this paper
• Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

  1998cited by this paper
• Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma

  1998cited by this paper
• Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma

  1997cited by this paper
• Dihydro‐5‐azacytidine in malignant mesothelioma

  1997cited by this paper
• Do authors of review articles use systematic methods to identify, assess and synthesize information?

  1997cited by this paper
• Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

  1997cited by this paper
• Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.

  1997cited by this paper
• Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

  1996cited by this paper
• Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta‐analysis

  1996cited by this paper
• Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.

  1996cited by this paper
• Two dose levels of ifosfamide in malignant mesothelioma.

  1996cited by this paper
• Chemotherapy in malignant pleural mesothelioma. A review.

  1996influential reference
• Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.

  1996cited by this paper
• Combined Chemotherapy in Pleurectomized Malignant Pleural Mesothelioma Patients

  1996cited by this paper
• Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.

  1996cited by this paper
• Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

  1995cited by this paper
• Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

  1995cited by this paper
• Oral etoposide in the treatment of malignant mesothelioma. A phase II study.

  1994cited by this paper
• Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.

  1994cited by this paper
• Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.

  1994cited by this paper
• Recombinant Interferon Alpha‐2b in the Treatment of Diffuse Malignant Pleural Mesothelioma

  1994cited by this paper
• Weekly high-dose cisplatin in malignant pleural mesothelioma.

  1994cited by this paper
• Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

  1994cited by this paper
• A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.

  1994cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• Clinical aspects of malignant mesothelioma in Australia.

  1993cited by this paper
• Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

  1993cited by this paper
• Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

  1993cited by this paper
• Effect of interferon-alpha 2a on malignant mesothelioma.

  1993cited by this paper
• Effect of Interferon-α2a Malignant Mesothelioma

  1993cited by this paper
• A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study

  1992cited by this paper
• High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.

  1992cited by this paper
• Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

  1992cited by this paper
• An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma

  1992cited by this paper
• Menogaril in the treatment of malignant mesothelioma: A phase II study

  1992cited by this paper
• Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.

  1992cited by this paper
• Activity of intrapleural recombinant gamma‐interferon in malignant mesothelioma

  1991cited by this paper
• Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study

  1991cited by this paper
• Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma

  1991cited by this paper
• Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.

  1991cited by this paper
• Epirubicin in the Treatment of Malignant Mesothelioma: A Phase II Cooperative Study

  1991cited by this paper
• Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.

  1991cited by this paper
• Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee.

  1991cited by this paper
• Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.

  1990cited by this paper
• Phase II trial of carboplatin in the management of malignant mesothelioma.

  1990cited by this paper
• A phase II study of pirarubicin in malignant pleural mesothelioma

  1990cited by this paper
• Phase II Evaluation of Recombinant Interferon-β (LFN-βser) in Patients with Diffuse Mesothelioma: A Southwest Oncology Group Study

  1990cited by this paper
• A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.

  1989cited by this paper
• A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study

  1988cited by this paper
• Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.

  1988cited by this paper
• A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma

  1988cited by this paper
• Phase II trial of vindesine in malignant pleural mesothelioma.

  1987cited by this paper
• Phase II trial of acivicin in malignant mesothelioma.

  1987cited by this paper
• Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.

  1987cited by this paper

• Mésothéliome pleural

  2024cites this paper
• Peritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes

  2023cites this paper
• Extrapelvic Endometriosis Mimicking Peritoneal Surface Malignancy: Case Report and a Review of Literature

  2022cites this paper
• Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin‐targeted therapies

  2021cites this paper
• Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• Extrapleural pneumonectomies for pleural mesothelioma

  2020cites this paper
• Mesothelioma: is chemotherapy alone a thing of the past?

  2020cites this paper
• Mésothéliome pleural malin

  2020cites this paper
• Novel Multitarget Therapies for Lung Cancer and Respiratory Disease

  2020cites this paper
• Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma

  2019cites this paper
• Tratamento Quimioterápico do Mesotelioma Pleural Maligno: Revisão Sistemática

  2019cites this paper
• Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014

  2019cites this paper
• Traitement chirurgical du mésothéliome pleural

  2019cites this paper
• The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

  2019cites this paper
• A Case of Peritoneal Sarcomatoid Mesothelioma with Absence of Occupationl Exposure to Asbestos

  2019cites this paper
• Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma

  2019cites this paper
• Gene expression of DNA repair proteins in colorectal cancer and medulloblastoma

  2019cites this paper
• Mesothelioma

  2019influential citation
• Development and Evaluation of Antibody Proteomics Technology for Rapid and Comprehensive Identification of Potential Biomarkers and Therapeutic Targets.

  2018cites this paper
• Malignant Pleural Mesothelioma and the Role of Non – Operative Therapies Kelvin

  2018cites this paper
• Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies

  2017cites this paper
• Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

  2017cites this paper
• Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

  2017cites this paper
• Novel systemic therapy against malignant pleural mesothelioma.

  2017cites this paper
• Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.

  2016cites this paper
• Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

  2016cites this paper
• Management of malignant pleural mesothelioma—part 2: therapeutic approaches

  2016cites this paper
• A catalogue of treatment and technologies for malignant pleural mesothelioma

  2016cites this paper
• Chapter 46 – Uncommon Thoracic Tumors

  2016cites this paper
• Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

  2016cites this paper
• Malignant mesothelioma

  2016cites this paper
• Maintenance chemotherapy with pemetrexed in patients with malignant pleural mesothelioma – case series and review of the literature

  2016cites this paper
• Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.

  2016cites this paper
• Management of Special Issues

  2015cites this paper
• Medical and oncological management of malignant mesothelioma.

  2015cites this paper
• An Update on Biomarkers and Treatment

  2015cites this paper
• Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII

  2015cites this paper
• Multimodality therapy for malignant pleural mesothelioma: surgery plus chemoradiotherapy?

  2015cites this paper
• Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.

  2015cites this paper
• Fast Neutron Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

  2015cites this paper
• Current issues in malignant pleural mesothelioma evaluation and management.

  2014cites this paper
• Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis

  2014cites this paper
• Mesotelioma peritoneal maligno en paciente sin exposición ocupacional. Reporte de un caso

  2014cites this paper
• The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms

  2014cites this paper
• Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.

  2014cites this paper
• Investigating heterogeneity of growth and drug response in mesotheliomas

  2013cites this paper
• Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.

  2013cites this paper
• Chapter 8 Mesothelioma : An Evidence-Based Review

  2013cites this paper
• Mesothelioma: An Evidence-Based Review

  2013cites this paper
• The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.

  2013cites this paper
• Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

  2013cites this paper
• Trattamento chirurgico del mesotelioma pleurico

  2013cites this paper
• Mesothelioma in relation to asbestos exposure in laboratory work

  2013cites this paper
• Sequence‑dependent effect of gemcitabine and cisplatin on A549 non‑small‑cell lung cancer cells.

  2013cites this paper
• Glutathione S‐transferase P1‐1 as a target for mesothelioma treatment

  2013cites this paper
• Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.

  2013cites this paper
• Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies

  2013cites this paper
• Malignant mesothelioma: new insights into a rare disease.

  2013cites this paper
• Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

  2013cites this paper
• [Malignant pleural mesothelioma: diagnosis and treatment].

  2013cites this paper
• Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens

  2013cites this paper
• The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.

  2012cites this paper
• Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

  2012cites this paper
• Management Options for Malignant Pleural Mesothelioma

  2012cites this paper
• Traitement chirurgical du mésothéliome pleural

  2012cites this paper
• Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.

  2012cites this paper
• Malignant pleural mesothelioma.

  2012cites this paper
• Mesothelioma: a review.

  2012cites this paper
• Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

  2012cites this paper
• Systemic treatment of malignant pleural mesothelioma.

  2012cites this paper
• First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial

  2012cites this paper
• Asbestos–Related Pleuropulmonary Diseases: Benign and Malignant

  2012cites this paper
• In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.

  2011cites this paper
• Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data

  2011cites this paper
• Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

  2011cites this paper
• A CASE OF PERITONEAL MESOTHELIOMA TREATED WITH CDDP AND PEMETREXED

  2011cites this paper
• Mesothelioma: an update

  2011influential citation
• Raltitrexed in mesothelioma

  2011cites this paper
• Pemetrexed+CDDP療法を実施した腹膜中皮腫の1例 第72巻09号2425頁

  2011cites this paper
• Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

  2011cites this paper
• European guidelines for the management of malignant pleural mesothelioma

  2011cites this paper
• Chemotherapy and radiotherapy for mesothelioma.

  2011cites this paper
• Investigational Approaches for Mesothelioma

  2011cites this paper
• Treated with Pemetrexed / Carboplatin PatientsGroup-1 as Predictors of Responsiveness in Mesothelioma Thymidylate Synthase and Excision Repair Cross-Complementing

  2011cites this paper
• [Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].

  2011cites this paper
• Therapie des nicht-resektablen malignen Pleuramesothelioms

  2011cites this paper
• Malignant pleural mesothelioma: the standard of care and challenges for future management.

  2011cites this paper
• Mésothéliome pleural malin

  2011cites this paper
• Advances in diagnosis and treatment of malignant pleural mesothelioma

  2011cites this paper
• Contribution of activin signals to progression of malignant pleural mesothelioma and evaluation of therapeutic implications

  2011cites this paper
• Thoracic malignancies, cisplatin and renal function

  2011cites this paper
• In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects

  2011cites this paper
• Uncommon Thoracic Tumors

  2011cites this paper
• Treatment of malignant pleural mesothelioma: current status and future directions.

  2010cites this paper
• Pemetrexed for malignant pleural mesothelioma: Is it a standard second‐line therapy?

  2010cites this paper
• 欧洲呼吸学会和欧洲胸外科医师学会恶性胸膜间皮瘤诊疗指南

  2010cites this paper
• Translational therapies for malignant pleural mesothelioma

  2010cites this paper
• European guidelines for the management of malignant pleural mesothelioma.

  2010cites this paper
• In vitro and in vivo therapeutic efficacy of the PPAR‐γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth

  2010cites this paper
• The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

  2010cites this paper